United Therapeutics (NASDAQ:UTHR) Issues Quarterly Earnings Results, Beats Estimates By $0.41 EPS

United Therapeutics (NASDAQ:UTHR) announced its earnings results on Wednesday. The biotechnology company reported $7.27 EPS for the quarter, topping the consensus estimate of $6.86 by $0.41, Briefing.com reports. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The business had revenue of $783.30 million during the quarter, compared to analysts’ expectations of $804.65 million. During the same quarter in the prior year, the company posted $6.41 earnings per share. The firm’s revenue was down 1.9% on a year-over-year basis.

Here are the key takeaways from United Therapeutics’ conference call:

• Positive Sentiment: United Therapeutics reported highly statistically significant results for the ADVANCE OUTCOMES study of ralinepag in PAH and submitted an NDA to the FDA, viewing the once-daily oral prostacyclin as a potential multibillion-dollar opportunity.
• Positive Sentiment: The company submitted an sNDA for nebulized Tyvaso in IPF after positive TETON results, with a potential 2027 approval; enrollment in the larger TETON PPF study is also nearly complete.
• Negative Sentiment: Second-quarter revenue was approximately $783 million, essentially flat sequentially and below management’s expectations. The company did not reaffirm or update its 2026 revenue-growth outlook, while nebulized Tyvaso remained pressured by increased competition.
• Positive Sentiment: Tyvaso DPI patient starts, referrals, total patients, and commercial patients reached record levels exiting the quarter, and a roughly doubled sales force began entering the field in July to improve physician reach and support second-half performance.
• Neutral Sentiment: United Therapeutics continues to advance its xenotransplantation pipeline, including UKidney, UThymoKidney, and EXPRESS-UHeart studies, while completing construction of commercial-scale facilities in Minnesota and Texas; however, these programs remain clinical-stage opportunities.

United Therapeutics Stock Down 1.3%

Shares of NASDAQ:UTHR traded down $6.73 during trading on Friday, hitting $526.21. 549,506 shares of the company were exchanged, compared to its average volume of 490,307. United Therapeutics has a 1-year low of $292.34 and a 1-year high of $609.35. The company has a market capitalization of $22.34 billion, a P/E ratio of 18.83, a price-to-earnings-growth ratio of 1.74 and a beta of 0.59. The business’s 50 day moving average is $539.78 and its 200-day moving average is $534.19.

Insider Transactions at United Therapeutics

In other news, CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $564.11, for a total transaction of $5,641,100.00. Following the sale, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at approximately $10,648,140.36. This trade represents a 34.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Over the last ninety days, insiders sold 482,833 shares of company stock valued at $265,555,592. 8.60% of the stock is owned by corporate insiders.

Institutional Trading of United Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in UTHR. Principal Securities Inc. increased its position in United Therapeutics by 4.7% in the fourth quarter. Principal Securities Inc. now owns 686 shares of the biotechnology company’s stock worth $334,000 after purchasing an additional 31 shares during the last quarter. WealthCollab LLC grew its stake in shares of United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 38 shares in the last quarter. Rakuten Securities Inc. grew its stake in shares of United Therapeutics by 76.7% in the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 46 shares in the last quarter. Wilmington Savings Fund Society FSB increased its holdings in shares of United Therapeutics by 125.6% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after buying an additional 49 shares during the last quarter. Finally, Meeder Advisory Services Inc. increased its holdings in shares of United Therapeutics by 8.5% in the 4th quarter. Meeder Advisory Services Inc. now owns 635 shares of the biotechnology company’s stock worth $310,000 after buying an additional 50 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. JPMorgan Chase & Co. increased their price objective on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. Bank of America dropped their target price on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a report on Friday, July 10th. Weiss Ratings downgraded United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a report on Friday, July 31st. Raymond James Financial started coverage on United Therapeutics in a research report on Friday, April 10th. They set an “outperform” rating and a $700.00 price target on the stock. Finally, Royal Bank Of Canada lowered their price target on shares of United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a report on Thursday. Eleven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, United Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $646.00.

Key Stories Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: EPS exceeded expectations. United Therapeutics reported second-quarter earnings of $7.27 per share, above the $6.86 consensus estimate and up from $6.41 a year earlier. The company also posted a robust 41.56% net margin, strengthening the fundamental case for UTHR. United Therapeutics Q2 Earnings Beat Estimates
• Positive Sentiment: Ralinepag and the broader pipeline provide future-growth catalysts. Phase 3 progress and regulatory filings for ralinepag could diversify United Therapeutics’ pulmonary hypertension business and help offset competitive pressure affecting Tyvaso. EPS Strength and Ralinepag’s Phase 3 Milestone
• Positive Sentiment: Analyst support remains favorable. H.C. Wainwright reiterated a Buy rating with a $660 price target. RBC kept an Outperform rating, although it reduced its target from $704 to $677. The analyst targets remain above the stock’s recently quoted level, suggesting continued perceived upside. Buy Rating Reiterated on United Therapeutics
• Neutral Sentiment: Revenue fell short of forecasts. Second-quarter revenue was $783.3 million, below the $804.65 million consensus and down 1.9% year over year. The revenue weakness reflects near-term commercial pressure, even though profitability and earnings were better than expected. United Therapeutics Q2 Net Income Rises, Revenue Falls
• Negative Sentiment: Senior executives sold sizable positions. CEO Martine Rothblatt sold 9,500 shares for approximately $4.9 million, while EVP Paul Mahon sold 8,300 shares for about $4.3 million. The sales may be routine or personal, but the reduction in insider ownership could weigh on investor confidence. United Therapeutics EVP Sells Shares

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.